Helion Increases Investment in China, Shanghai Lingang Production Base Project Officially Launched

Recently, Haleon announced an investment of approximately £65 million (nearly 600 million RMB). The Lingang New Area Administrative Committee and Haleon (China) Co., Ltd. signed a project investment agreement in Shanghai, officially establishing the Haleon Oral Health Shanghai Lingang Production Base Project.

This investment is not only another important milestone in Haleon’s strategic focus on China but also a positive response to the national “14th Five-Year Plan” and its “Health Priority Development” policy. The goal is to strengthen the supply chain through self-built capacity, better meeting the growing demand of Chinese consumers for high-quality, scientifically validated oral care solutions.

Haleon CEO Brian McNamara stated, “China is a strategic priority market for Haleon. This investment reflects our long-term commitment to bringing world-leading research and innovation to Chinese consumers and improving public health and well-being. Leveraging global R&D capabilities, combined with deep local insights, manufacturing, and research and development, we are dedicated to providing scientifically validated, high-quality products that genuinely improve people’s daily health.”

Investing in “Made in Shanghai” to Build an Agile Supply Chain

The new oral health production base will be located in Shanghai Lingang New Area. As Haleon China’s headquarters, Shanghai’s world-class industrial ecosystem and talent advantages provide a solid foundation for business development. The Lingang New Area offers significant policy benefits, convenient cross-border capital flow, comprehensive industrial support, bonded zone policies, and efficient logistics hubs, making it an ideal location for high-end manufacturing.

The factory will integrate advanced manufacturing technologies and digital management methods. Through self-built capacity, Haleon aims to accelerate innovation and respond more swiftly to the evolving preferences of Chinese consumers.

Empowering the Entire Lifecycle, Starting with Oral Health Education

Aligned with the “Healthy China” initiative’s requirements for lifecycle health management and key population coverage, Haleon recognizes that improving national oral health depends not only on products but also on education and prevention. Since 2023, Haleon has actively supported and deeply participated in the “Healthy Teeth China Tour” initiated by the China Oral Disease Prevention Foundation. By establishing a collaborative platform involving government, academia, experts, and mainstream media, it mobilizes social forces, empowers oral health professionals, promotes public oral health science, and enhances overall health.

From local product innovation to supply chain strengthening and ongoing science education, Haleon is committed to achieving its 2030 vision for oral health in China: helping 200 million children prevent cavities, enabling 300 million adults to overcome tooth sensitivity, assisting 400 million seniors to enjoy food easily, and protecting the gum health of 1 billion adults.

Deep Roots in China for Over 40 Years, Confidence Steadfast

As a company with over 40 years of deep engagement in the Chinese market, Haleon owns many trusted brands among consumers and professionals. It remains committed to “people-oriented, enhancing daily health.” Following Haleon’s recent full acquisition of Tianjin Shike Pharmaceutical Co., Ltd. in China and the U.S., a series of actions demonstrate Haleon’s firm confidence in the long-term growth of the Chinese market.